Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy
- 26 February 2012
- journal article
- review article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 61 (5) , 599-614
Abstract
The thymus is a central lymphoid organ with crucial role in generating T cells and maintaining homeostasis of the immune system. More than 30 peptides, initially referred to as “thymic hormones,” are produced by this gland. Although the majority of them have not been proven to be thymus-specific, thymic peptides comprise an effective group of regulators, mediating important immune functions. Thymosin fraction five (TFV) was the first thymic extract shown to stimulate lymphocyte proliferation and differentiation. Subsequent fractionation of TFV led to the isolation and characterization of a series of immunoactive peptides/polypeptides, members of the thymosin family. Extensive research on prothymosin α (proTα) and thymosin α1 (Tα1) showed that they are of clinical significance and potential medical use. They may serve as molecular markers for cancer prognosis and/or as therapeutic agents for treating immunodeficiencies, autoimmune diseases and malignancies. Although the molecular mechanisms underlying their effect are yet not fully elucidated, proTα and Tα1 could be considered as candidates for cancer immunotherapy. In this review, we will focus in principle on the eventual clinical utility of proTα, both as a tumor biomarker and in triggering anticancer immune responses. Considering the experience acquired via the use of Tα1 to treat cancer patients, we will also discuss potential approaches for the future introduction of proTα into the clinical setting.Keywords
This publication has 102 references indexed in Scilit:
- Overexpression of Prothymosin Alpha Predicts Poor Disease Outcome in Head and Neck CancerPLOS ONE, 2011
- HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigenVaccine, 2010
- Prothymosin-α inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon inductionProceedings of the National Academy of Sciences, 2010
- Nrf2 signaling and cell survivalToxicology and Applied Pharmacology, 2010
- High-mobility group box 1 and cancerBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2010
- A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinomaHepatology International, 2009
- Prothymosin α immunoactive carboxyl-terminal peptide TKKQKTDEDD stimulates lymphocyte reactions, induces dendritic cell maturation and adopts a β-sheet conformation in a sequence-specific mannerMolecular Immunology, 2009
- Immunocytological and Preliminary Immunohistochemical Studies of Prothymosin α, a Human Cancer–associated Polypeptide, With a Well-characterized Polyclonal AntibodyJournal of Histochemistry & Cytochemistry, 2008
- Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-αl and interferon-α2aEuropean Journal of Cancer, 1995
- Tissue concentrations of prothymosin alpha: A novel proliferation index of primary breast cancerEuropean Journal of Cancer, 1993